BC
TSVT

Birchview Capital’s 2seventy bio TSVT Stock Holding History

Birchview Capital’s Portfolio TSVT Stock Details TSVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,500
Closed -$76.6K – 80
2025
Q1 		$76.6K Sell
15,500
-333
-2% -$1.06K 0.07% 63
2024
Q4 		$46.5K Hold
15,833
– – 0.04% 67
2024
Q3 		$74.7K Sell
15,833
-2,000
-11% -$9.02K 0.06% 56
2024
Q2 		$68.7K Sell
17,833
-2,000
-10% -$9.02K 0.06% 56
2024
Q1 		$106K Hold
19,833
– – 0.09% 55
2023
Q4 		$84.7K Sell
19,833
-40,000
-67% -$123K 0.07% 55
2023
Q3 		$235K Hold
59,833
– – 0.2% 43
2023
Q2 		$606K Hold
59,833
– – 0.45% 34
2023
Q1 		$610K Hold
59,833
– – 0.48% 29
2022
Q4 		$561K Hold
59,833
– – 0.4% 31
2022
Q3 		$871K Hold
59,833
– – 0.61% 29
2022
Q2 		$790K Buy
59,833
+25,500
+74% +$347K 0.57% 27
2022
Q1 		$586K Buy
34,333
+6,334
+23% +$107K 0.42% 39
2021
Q4 		$718K Buy
+27,999
New +$873K 0.46% 35

Other funds holding TSVT

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Birchview Capital's TSVT Position: Q2 2025 in Review

Birchview Capital sold out of 2seventy bio (TSVT) in Q2 2025, closing a stake of 15,500 shares — an estimated $76.6K sold.

Birchview Capital first reported a position in TSVT in Q4 2021 and held it in 14 quarters. The position peaked at $871K in Q3 2022. 2 funds tracked by Wall St. Rank hold TSVT as of Q2 2025.

  • Birchview Capital reported no remaining 2seventy bio position as of Q2 2025 after selling out during the quarter.
  • Birchview Capital sold 15,500 2seventy bio shares in Q2 2025, an estimated $76.6K.
  • Birchview Capital first reported a position in 2seventy bio in Q4 2021 and held it in 14 quarters.
  • Birchview Capital's 2seventy bio position peaked at $871K in Q3 2022.
  • 2 funds tracked by Wall St. Rank held 2seventy bio as of Q2 2025.

Based on Birchview Capital's 13F filing for Q2 2025, filed 14 Aug 2025.